Sequenom Inc. has acquired exclusive worldwide rights (excluding Hong Kong) to digital PCR and other noninvasive prenatal diagnostic intellectual property from The Chinese University of Hong Kong. These rights expand Sequenom’s already existing, broad intellectual property portfolio of noninvasive prenatal diagnostic methods using fetal nucleic acids obtained from a maternal sample. The agreement expands Sequenom’s leadership position as it continues to advance its clinical development programs and marketing plans for its proprietary, noninvasive Trisomy 21 Down syndrome maternal blood test and other innovative prenatal diagnostic tests.